AR095534A1 - Combinaciones de inhibidores de la quinasa de tirosina de bruton e inhibidores de cyp3a4 - Google Patents
Combinaciones de inhibidores de la quinasa de tirosina de bruton e inhibidores de cyp3a4Info
- Publication number
- AR095534A1 AR095534A1 ARP140101144A ARP140101144A AR095534A1 AR 095534 A1 AR095534 A1 AR 095534A1 AR P140101144 A ARP140101144 A AR P140101144A AR P140101144 A ARP140101144 A AR P140101144A AR 095534 A1 AR095534 A1 AR 095534A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyp3a4
- inhibitors
- inhibitor
- pharmaceutical composition
- cyp3a4 inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Combinaciones de inhibidores de la quinasa de tirosina de Bruton (Btk), tales como la 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-iI)piperidin-1-iI)prop-2-en-1-ona e inhibidores de CYP3A4. Métodos para tratar el cáncer y las enfermedades autoinmunes, que están basados en la administración de combinaciones de inhibidores de la quinasa de tirosina de Bruton (Btk), tales como la 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-iI)piperidin-1-iI)prop-2-en-1-ona e inhibidores de CYP3A4. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende, a) una cantidad terapéuticamente eficaz de lbrutinib; b) un inhibidor de CYP3A4; y c) un excipiente farmacéuticamente aceptable. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque el inhibidor de CYP3A4 es: un antiarrítmico; una antihistamina; un antifúngico de azol; una benzodiazepina; un bloqueante de canales de calcio; un antiviral para HIV; un inhibidor de HMG CoA Reductasa; un antibiótico macrólido; un procinético; un inhibidor de proteasa; o cualquier combinación de los mismos. Reivindicación 4: La composición farmacéutica de la reivindicación 3, caracterizada porque el inhibidor de CYP3A4 es cobicistat (GS-9350) o análogos o derivados de cobicistat (GS-9350). Reivindicación 6: La composición farmacéutica de la reivindicación 3, caracterizada porque el inhibidor de CYP3A4 es ritonavir. Reivindicación 7: La composición farmacéutica de la reivindicación 1, caracterizada porque la cantidad terapéuticamente eficaz de lbrutinib es de entre aproximadamente 10 mg y aproximadamente 100 mg. Reivindicación 11: Un método para tratar un trastorno proliferativo a células B en un individuo que lo necesite caracterizado porque comprende administrar una combinación de: a) una cantidad terapéuticamente eficaz de Ibrutinib; y b) un inhibidor de CYP3A4. Reivindicación 12: El método de la reivindicación 11, caracterizado porque el trastorno proliferativo a células B es leucemia linfocítica crónica (CLL), linfoma linfocítico pequeño (SLL), CLL de alto riesgo, o un linfoma no CLL/SLL. Reivindicación 25: El método de la reivindicación 11, caracterizado porque el lbrutinib y el inhibidor de CYP3A4 están en una forma de dosificación combinada. Reivindicación 26: El método de la reivindicación 11, caracterizado porque el Ibrutinib y el inhibidor de CYP3A4 están en formas de dosificación separadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784119P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095534A1 true AR095534A1 (es) | 2015-10-21 |
Family
ID=51625242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101144A AR095534A1 (es) | 2013-03-14 | 2014-03-14 | Combinaciones de inhibidores de la quinasa de tirosina de bruton e inhibidores de cyp3a4 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160022683A1 (es) |
| EP (1) | EP2968341A4 (es) |
| JP (1) | JP2016512549A (es) |
| KR (1) | KR20160006668A (es) |
| CN (1) | CN105073115A (es) |
| AR (1) | AR095534A1 (es) |
| AU (1) | AU2014244518A1 (es) |
| BR (1) | BR112015021995A2 (es) |
| CA (1) | CA2902613A1 (es) |
| EA (1) | EA201591718A1 (es) |
| HK (1) | HK1224173A1 (es) |
| IL (1) | IL240818A0 (es) |
| MX (1) | MX2015011733A (es) |
| PH (1) | PH12015502053A1 (es) |
| TW (1) | TW201440772A (es) |
| WO (1) | WO2014159745A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK) |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| DK3689878T3 (da) | 2011-07-19 | 2021-11-08 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異 |
| ES2738493T3 (es) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
| EP3060218A4 (en) * | 2013-10-25 | 2017-07-19 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
| WO2015083008A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
| PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| TW201628622A (zh) * | 2014-11-17 | 2016-08-16 | 製藥公司 | Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合 |
| JP2018503610A (ja) * | 2014-12-23 | 2018-02-08 | ファーマサイクリックス エルエルシー | Ｂｔｋ阻害剤の組み合わせ及び投与レジメン |
| MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
| KR20170134462A (ko) | 2015-04-13 | 2017-12-06 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 btk 저해제의 병용 치료법 |
| PT3954690T (pt) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| WO2017023047A1 (ko) * | 2015-08-03 | 2017-02-09 | 성균관대학교산학협력단 | 아리피프라졸을 유효성분으로 함유하는 염증성 질환 또는 암 예방 또는 치료용 조성물 |
| CN106474478A (zh) * | 2015-08-27 | 2017-03-08 | 北京美倍他药物研究有限公司 | 依鲁替尼的药物组合物 |
| EP3405178A1 (en) * | 2016-01-19 | 2018-11-28 | Janssen Pharmaceutica NV | Formulations/compositions comprising a btk inhibitor |
| MA45848A (fr) * | 2016-08-04 | 2019-06-12 | Gilead Sciences Inc | Cobicistat destiné à être utilisé dans des traitements du cancer |
| US20210000815A1 (en) * | 2017-12-28 | 2021-01-07 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
| US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
| CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| AU2019261986A1 (en) | 2018-05-03 | 2020-11-26 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (CAR) T cell therapy and a kinase inhibitor |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CN109157660A (zh) * | 2018-10-28 | 2019-01-08 | 黄泳华 | 含有蛋白激酶抑制剂与西地那非的组合物 |
| CN109045300A (zh) * | 2018-11-04 | 2018-12-21 | 黄泳华 | 含有磷酸二酯酶抑制剂纳米粒与蛋白激酶抑制剂的组合物 |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| TW202131906A (zh) * | 2019-11-21 | 2021-09-01 | 美商神經治療股份有限公司 | ***二酚及／或Ｃｏｂｉ（考比司他）聯合藥物治療 |
| BR112022013547A2 (pt) * | 2020-01-10 | 2022-09-06 | Takeda Pharmaceuticals Co | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição |
| IL308668A (en) * | 2021-05-21 | 2024-01-01 | Trevor Klee | Preparations for the treatment of autoimmune, alloimmune, and inflammatory disorders and mitochondrial conditions and their uses |
| CN114469952B (zh) * | 2022-03-02 | 2023-09-19 | 中南大学湘雅三医院 | 特拉匹韦在制备malt1抑制剂、抗malt1依赖性肿瘤的药物中的应用及抗肿瘤药物 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2530083T1 (sl) * | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
| US20100069458A1 (en) * | 2007-02-15 | 2010-03-18 | Peter Wisdom Atadja | Combination of lbh589 with other therapeutic agents for treating cancer |
| CA2680589A1 (en) * | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
| US8809273B2 (en) * | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| EP2575818A4 (en) * | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK) |
| CN105209068A (zh) * | 2013-02-07 | 2015-12-30 | 免疫医疗公司 | 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox) |
-
2014
- 2014-03-12 KR KR1020157027251A patent/KR20160006668A/ko not_active Application Discontinuation
- 2014-03-12 CN CN201480012343.8A patent/CN105073115A/zh active Pending
- 2014-03-12 CA CA2902613A patent/CA2902613A1/en not_active Abandoned
- 2014-03-12 AU AU2014244518A patent/AU2014244518A1/en not_active Abandoned
- 2014-03-12 EP EP14774808.1A patent/EP2968341A4/en not_active Withdrawn
- 2014-03-12 MX MX2015011733A patent/MX2015011733A/es unknown
- 2014-03-12 JP JP2016501705A patent/JP2016512549A/ja active Pending
- 2014-03-12 EA EA201591718A patent/EA201591718A1/ru unknown
- 2014-03-12 BR BR112015021995A patent/BR112015021995A2/pt not_active Application Discontinuation
- 2014-03-12 US US14/774,292 patent/US20160022683A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/024966 patent/WO2014159745A1/en active Application Filing
- 2014-03-14 TW TW103109286A patent/TW201440772A/zh unknown
- 2014-03-14 AR ARP140101144A patent/AR095534A1/es unknown
-
2015
- 2015-08-25 IL IL240818A patent/IL240818A0/en unknown
- 2015-09-11 PH PH12015502053A patent/PH12015502053A1/en unknown
-
2016
- 2016-07-04 HK HK16107733.9A patent/HK1224173A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2902613A1 (en) | 2014-10-02 |
| JP2016512549A (ja) | 2016-04-28 |
| EP2968341A1 (en) | 2016-01-20 |
| AU2014244518A1 (en) | 2015-09-17 |
| WO2014159745A1 (en) | 2014-10-02 |
| CN105073115A (zh) | 2015-11-18 |
| BR112015021995A2 (pt) | 2017-07-18 |
| PH12015502053A1 (en) | 2016-01-18 |
| IL240818A0 (en) | 2015-10-29 |
| EA201591718A1 (ru) | 2016-05-31 |
| TW201440772A (zh) | 2014-11-01 |
| EP2968341A4 (en) | 2016-11-23 |
| MX2015011733A (es) | 2016-04-25 |
| HK1224173A1 (zh) | 2017-08-18 |
| US20160022683A1 (en) | 2016-01-28 |
| KR20160006668A (ko) | 2016-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095534A1 (es) | Combinaciones de inhibidores de la quinasa de tirosina de bruton e inhibidores de cyp3a4 | |
| CL2019002150A1 (es) | Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073) | |
| DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| UY37926A (es) | Formulaciones de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| CL2015001160A1 (es) | Compuestos derivados triciclicos fusionados de tiofeno, inhibidores de la cinasa janus (jak); composicion farmaceutica que los comprende; metodo para inhibir la actividad de jak1; metodo para tratar una enfermedad autoinmunitaria, un cancer, un trastorno mieloproliferativo y una enfermedad inflamatoria, entre otras enfermedades. | |
| ES2636936T3 (es) | Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer | |
| NI201600049A (es) | Inhibidores de kras g12c | |
| NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CL2014001529A1 (es) | Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades. | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| NI201000002A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k. | |
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| BR112015025711A8 (pt) | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| BR112015031027A2 (pt) | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única | |
| AR075369A1 (es) | Comprimidos para terapia de combinacion para el tratamiento de infecciones virales. | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| AR108889A1 (es) | Combinaciones para el tratamiento del cáncer | |
| CR20190310A (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
| IL291452A (en) | Dosage forms for tyk2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |